Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shield Therapeutics ( (GB:STX) ) has issued an update.
Shield Therapeutics has appointed Anders Lundstrom as the permanent CEO, highlighting his significant contributions as interim CEO in enhancing the company’s growth and operational efficiency. Lundstrom’s leadership has been pivotal in increasing revenues and operational streamlining, positioning the company toward its goal of becoming cash flow positive by the end of 2025. The appointment is expected to further strengthen Shield’s strategic objectives and stakeholder value, especially in the treatment of iron deficiency with ACCRUFeR®.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial stage specialty pharmaceutical company focused on addressing iron deficiency through its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). As the first FDA approved oral iron treatment for iron deficiency and iron deficiency anemia, ACCRUFeR® is marketed in the U.S. in collaboration with Viatris Inc. and has licensing agreements in several international markets. The product is targeted to meet significant unmet medical needs and holds patent coverage until the mid-2030s.
YTD Price Performance: 11.11%
Average Trading Volume: 2,806,936
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £31.25M
Learn more about STX stock on TipRanks’ Stock Analysis page.